Testing effectiveness (Phase 2)Active Not RecruitingNCT06008093
What this trial is testing
Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 103